1. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases
- Author
-
Johanna I. Kiiski, Miguel Urioste, Melissa C. Southey, Ramunas Janavicius, Finn Cilius Nielsen, Ana Vega, Irene Konstantopoulou, Ana Blanco, Jesús del Valle, Joan Brunet, Emma Tham, Daniele Calistri, Esther Darder, Taru A. Muranen, Maria Rossing, Åke Borg, Aleksander Myszka, Marketa Janatova, Drakoulis Yannoukakos, Laura Papi, Paolo Peterlongo, Bernardo Bonanni, Florentia Fostira, Catarina Santos, Séverine Eon-Marchais, Anders Kvist, Petra Kleiblova, Snezhana Smichkoska, Manuel R. Teixeira, Vilius Rudaitis, Dijana Plaseska-Karanfilska, Conxi Lázaro, Alicia Barroso, Ugnius Mickys, Mariarosaria Calvello, Edith Olah, Virginie Moncoutier, Zdenek Kleibl, Nadine Andrieu, Rimvydas Norvilas, Stepan Chvojka, Paolo Radice, Jana Soukupova, Birgitte Bertelsen, Siranoush Manoukian, Claude Houdayer, Marta Santamariña, Bernard Peissel, Zdenka Vlckova, Ana Osorio, Laura Cortesi, Jacopo Azzollini, Katerina Kubelka-Sabit, Fabienne Lesueur, Valentina Zampiga, Tu Nguyen-Dumont, Javier Benitez, Gisella Figlioli, Hans Ehrencrona, Orland Diez, Therese Törngren, Judith Balmaña, Francesca Gensini, Ruta Marcinkute, Timea Pocza, Angela Toss, Dominique Stoppa-Lyonnet, Ana Peixoto, Heli Nevanlinna, Institut Català de la Salut, [Figlioli G] Genome Diagnostics Program, IFOM - the FIRC Institute for Molecular Oncology, Milan, Italy. [Kvist A] Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. [Tham E] Department of Clinical Genetics, Karolinska University Hospital and Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. [Soukupova J] Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic. [Kleiblova P] Institute of Biology and Medical Genetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. [Muranen TA] Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, HUS, Helsinki, Finland. [Balmaña J] Hereditary Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Diez O] Hereditary Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Àrea de Genètica Clínica i Molecular, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Italian Association for Cancer Research, Fondazione Umberto Veronesi, Ministero della Salute (Italia), Region Stockholm (ALF), Ministry of Health (República Checa), Unión Europea. Comisión Europea, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red - CIBERER (Enfermedades Raras), French National Institute of Cancer (INCa grant), National Health and Medical Research Council (Australia), Hungarian Research Grants, Lietuvos Mokslo Taryba (Lituania), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministry of Health, Italy, Ministry of Health, Czech Republic, European Commission, Instituto de Salud Carlos III - ISCIII, Spanish Network on Rare Diseases (CIBERER), National Health and Medical Research Council of Australia, Research Council of Lithuania (LMTLT), European Regional Development Fund (ERDF/FEDER), HUS Gynecology and Obstetrics, Department of Obstetrics and Gynecology, Helsinki University Hospital Area, University of Helsinki, INDIVIDRUG - Individualized Drug Therapy, and Clinicum
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Breast cancer risk factors ,Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] ,ptvs ,Càncer - Aspectes genètics ,Basic medicine ,Breast cancer ,0302 clinical medicine ,Mama - Càncer ,hemic and lymphatic diseases ,FANCM ,Breast cancer predisposition ,FANCM truncating variants ,Mutation spectrum ,PTVs ,RISK ,neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] ,Factors de risc en les malalties ,Otros calificadores::Otros calificadores::/genética [Otros calificadores] ,FANCM GENE ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,030220 oncology & carcinogenesis ,Gene sequence ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Risk factors in diseases ,3122 Cancers ,lcsh:RC254-282 ,fancm truncating variants ,Càncer de mama ,breast cancer predisposition ,breast cancer risk factors ,mutation spectrum ,03 medical and health sciences ,Internal medicine ,Other subheadings::Other subheadings::/genetics [Other subheadings] ,medicine ,ANEMIA ,Allele frequency ,Female breast cancer ,MUTATIONS ,business.industry ,nutritional and metabolic diseases ,BRCA1 ,medicine.disease ,GENE ,030104 developmental biology ,Clinical medicine ,C.5791C-GREATER-THAN-T ,FANCM Protein ,business - Abstract
Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2&ndash, 4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases.
- Published
- 2020